Abstract:
OBJECTIVE To explore the new path of high-quality development of China's pharmaceutical industry under the big data strategy.
METHODS Combed the actual performance of digital transformation of pharmaceutical industry in Jiangsu Province, and summarized the experience of digital transformation and governance of pharmaceutical industry in developed countries.
RESULTS China's pharmaceutical industry could actively draw on the advanced concepts and practices of international pharmaceutical "digital-intelligent supervision", based on the actual conditions and development stage of the domestic pharmaceutical sector, focusing on key areas such as data element-driven development, information synchronization capability, and resource security to accelerate digital transformation. At the same time, efforts should be made to promote the establishment of a diversified co-governance framework led by the government, with enterprises as the main body, coordinated by medical institutions, and involving public participation, in order to enhance regulatory efficiency and promote high-quality development of the industry.
CONCLUSION A collaborative governance programme for high quality development based on the RACI model can help the pharmaceutical industry with efficient full-cycle management.